The NEDD4-2 antibody is a crucial tool for studying the neural precursor cell-expressed developmentally downregulated 4-like (NEDD4L or NEDD4-2) protein, a member of the HECT-type E3 ubiquitin ligase family. NEDD4-2 regulates membrane protein stability and trafficking by tagging substrates with ubiquitin, targeting them for degradation or altering their cellular localization. It plays a pivotal role in controlling epithelial sodium channels (ENaC), voltage-gated ion channels, and neurotransmitter transporters, linking it to hypertension, cystic fibrosis, neurodevelopmental disorders, and cancer. Dysregulation of NEDD4-2 has been implicated in diseases like Liddle syndrome (due to ENaC overactivation) and various cancers through interactions with PTEN, EGFR, and TGF-β signaling pathways. The antibody is widely used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to assess protein expression, post-translational modifications, and subcellular distribution. Researchers often validate its specificity using knockout controls or siRNA-mediated knockdown. Commercial NEDD4-2 antibodies typically target conserved regions, such as the HECT domain or WW protein interaction motifs, and vary in reactivity across species (human, mouse, rat). Its development has advanced understanding of ubiquitin-dependent signaling networks and therapeutic targeting of E3 ligases in precision medicine.